Published in Int J Cancer on March 15, 2010
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Visual gene-network analysis reveals the cancer gene co-expression in human endometrial cancer. BMC Genomics (2014) 0.86
MHC class II expression in pancreatic tumors: a link to intratumoral inflammation. Virchows Arch (2011) 0.83
Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2014) 0.80
HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. Mol Med (2015) 0.79
NLRC5 expression in tumors and its role as a negative prognostic indicator in stage III non-small-cell lung cancer patients. Oncol Lett (2015) 0.79
Clinical implications of human leukocyte antigen class I expression in endometrial cancer. Mol Clin Oncol (2015) 0.78
In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. Int J Mol Sci (2016) 0.78
The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol (2013) 0.78
Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer. Oncotarget (2016) 0.76
Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. Br J Cancer (2015) 0.75
Impact of HLA-G analysis in prevention, diagnosis and treatment of pathological conditions. World J Methodol (2014) 0.75
Cancer treatment and the KIR-HLA system: an overview. Clin Exp Med (2017) 0.75
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Management of lung nodules detected by volume CT scanning. N Engl J Med (2009) 6.79
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol (2010) 2.12
Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res (2010) 2.03
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol (2005) 2.01
Features of resolving and nonresolving indeterminate pulmonary nodules at follow-up CT: the NELSON study. Radiology (2013) 1.98
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. Lancet Oncol (2010) 1.84
Introduction of the implantable Doppler system did not lead to an increased salvage rate of compromised flaps: a multivariate analysis. Plast Reconstr Surg (2010) 1.82
In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med (2007) 1.79
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging (2013) 1.70
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol (2009) 1.53
Effect of nodule characteristics on variability of semiautomated volume measurements in pulmonary nodules detected in a lung cancer screening program. Radiology (2008) 1.46
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol (2009) 1.44
Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.43
Quality-of-life outcomes between mastectomy alone and breast reconstruction: comparison of patient-reported BREAST-Q and other health-related quality-of-life measures. Plast Reconstr Surg (2013) 1.43
Systematic screening for urinary incontinence in older women: who could benefit from it? Scand J Prim Health Care (2012) 1.42
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
Severity, not type, is the main predictor of decreased quality of life in elderly women with urinary incontinence: a population-based study as part of a randomized controlled trial in primary care. Health Qual Life Outcomes (2012) 1.41
Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41
The effect of systematic screening of older women for urinary incontinence on treatment uptake: the URINO trial. Maturitas (2013) 1.39
Impact of urinary incontinence on sexual functioning in community-dwelling older women. J Sex Med (2014) 1.39
Amplicon mapping and expression profiling identify the Fas-associated death domain gene as a new driver in the 11q13.3 amplicon in laryngeal/pharyngeal cancer. Clin Cancer Res (2007) 1.37
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Estimation and prediction in a multi-state model for breast cancer. Biom J (2006) 1.36
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res (2010) 1.27
Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res (2009) 1.27
Tissue distribution of the death ligand TRAIL and its receptors. J Histochem Cytochem (2004) 1.27
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Saline contrast hysterosonography in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG (2003) 1.24
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med (2010) 1.23
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat (2010) 1.20
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol Oncol (2008) 1.19
Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol (2003) 1.17
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes. Proc Natl Acad Sci U S A (2011) 1.17
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
An oncological view on the blood-testis barrier. Lancet Oncol (2002) 1.15
Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer (2011) 1.14
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Vulvar carcinoma. The price of less radical surgery. Cancer (2002) 1.12
Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. Eur J Radiol (2007) 1.11
The effect of chemotherapy on expression of folate receptor-alpha in ovarian cancer. Cell Oncol (Dordr) (2011) 1.10
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat (2008) 1.09
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer (2006) 1.08
Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol (2006) 1.08
Do breast cancer survivors visit their general practitioner for psychological problems? Reply to: Heins et al.: For which health problems do cancer survivors visit their general practitioner? Eur J Cancer (2013) 1.08
Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability. Eur Radiol (2009) 1.08
Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat (2010) 1.07
PMS2 involvement in patients suspected of Lynch syndrome. Genes Chromosomes Cancer (2009) 1.07
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
Targeted exome sequencing in clear cell renal cell carcinoma tumors suggests aberrant chromatin regulation as a crucial step in ccRCC development. Hum Mutat (2012) 1.06
Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals. Eur Radiol (2013) 1.06
CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer (2013) 1.06
Costs and effects of abdominal versus laparoscopic hysterectomy: systematic review of controlled trials. PLoS One (2009) 1.05
As good as it gets? A meta-analysis and systematic review of methodological quality of heart rate variability studies in functional somatic disorders. Biol Psychol (2009) 1.05
Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03